Magnetic particle imaging may help tailor cell therapy delivery, mouse study suggests

by Alexandria Carolan, Johns Hopkins University School of Medicine

edited by Lisa Lock, reviewed by Andrew Zinin

Lisa Lock

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Lead Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add as preferred source

Scientists at Johns Hopkins Medicine say they used a form of magnetic imaging to track cell therapy injections commonly used to treat certain autoimmune diseases and cancers. The findings, from a study of mice, add to a growing body of evidence that magnetic particle imaging (MPI), a new technique that allows scientists to visualize therapeutic cells as they inject them, may eventually help researchers personalize cell therapy treatments for individual patients. The study is published in Science Advances.

Existing cell therapies include CAR-T cell therapy, in which an individual's immune cells are engineered to seek and destroy cancer cells. The problem with CAR-T cell therapy is that available imaging technology, including conventional MRI and CT scanners, does not allow clinicians to see how many cells are actually delivered and where, and how many of these cells end up targeting a tumor or inflammatory tissues, says corresponding author Jeff Bulte, M.S., Ph.D., professor of radiology and radiological science at the Johns Hopkins University School of Medicine and director of cellular imaging for the Johns Hopkins Institute for Cell Engineering.

"Using MPI, we can visualize where therapeutic cells end up in the body," says Bulte. "Our research suggests MPI is a promising avenue for helping determine a more precise dose of cell therapy for individual patients."

In experiments, the scientists used mesenchymal stem cells (about 25 micrometers), which are commonly studied as a potential avenue for cell therapy to fight autoimmune diseases and cancer in clinical trials, and smaller neural precursor cells (about 10 micrometers) derived from induced pluripotent stem cells.

"Selecting these large and small cells can help us compare the effect of cell size and delivery route for cell therapy treatments," says first author Ali Shakeri-Zadeh, Ph.D., assistant professor of radiology and radiological science and a member of the Institute for Cell Engineering.

By labeling the cells engineered to fight disease, injecting them into normal mice as well as mice with autoimmune encephalomyelitis, then imaging these cells with MPI, Bulte says this technology can potentially help scientists develop more effective treatments for certain cancers, autoimmune diseases including multiple sclerosis (MS), and other neurological conditions such as ALS.

The scientists tagged both cell types with a specialized ultra-tiny nanoparticle, "superparamagnetic iron oxide nanoparticles." Once labeled with these magnetic nanoparticles, the scientists injected the larger mesenchymal stem cells into mice with experimental autoimmune encephalomyelitis (EAE), a commonly used model for studying MS, and into normal mice.

Using MPI, the scientists visualized how many cells were effectively delivered and where they went.

After using MPI to observe the mice, the scientists say injecting the cells into the artery was an effective method of cell therapy delivery, resulting in more cells that were delivered directly to the key target organs to fight disease, including the brain and spleen. The scientists also observed cell accumulation in other organs, including the lungs and liver. The scientists did these same experiments in normal mice, and found that cells similarly traveled to the lungs, liver and brain, but could not be observed at detectable levels in the spleen.

"In autoimmune diseases, particularly MS, it's thought that harmful immune cells, or T cells, are released from the spleen," says Shakeri-Zadeh. "Our experiments in EAE mice, a mouse model of MS, show that therapeutic cells could subdue harmful immune cells right at the source, in the spleen."

The scientists caution that, though cell delivery to the brain through the artery was shown to be effective in terms of accumulating and fighting disease hot spots, the best method to deliver cell therapy may vary from person to person.

In the future, scientists say they intend to broaden these experiments and use MPI to find more effective ways to deliver cell therapy in cancer as well as neurologic diseases.

"If used on a large scale, MPI cytometry has the potential to help personalize treatments for each patient receiving cell therapy treatment," Bulte says.

Publication details

Ali Shakeri-Zadeh et al, Whole-body in vivo MPI cytometry reveals injection route-, dose-, cell size–, and disease-dependent differences in organ distribution, Science Advances (2026). DOI: 10.1126/sciadv.aec4482

Journal information: Science Advances

Key medical concepts

Mesenchymal Stem CellsCAR T Cell Therapy

Clinical categories

Diagnostic radiologyNeurology Provided by Johns Hopkins University School of Medicine Who's behind this story?

Lisa Lock

BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Magnetic particle imaging may help tailor cell therapy delivery, mouse study suggests (2026, June 1) retrieved 1 June 2026 from https://medicalxpress.com/news/2026-06-magnetic-particle-imaging-tailor-cell.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.